NovoCure Limited (NVCR) News
Follow NovoCure Limited (NVCR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Novocure's Optune Pax Approved in Japan for Pancreatic Cancer
Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, when used concomitantly with gemcitabine and nab-paclita
EQUITY | Oct 01, 2026, 01:00 PM UTC
L
NVCR: Growth in oncology franchises and global expansion drive profitability and pipeline momentum
Disciplined investment and cost controls have reignited GBM growth and enabled global expansion, with strong launches in pancreatic and lung cancer, especially in Japan. Profitability is within reach, and clinical trials
NEWS | Sep 14, 2026, 08:29 PM UTC
L
NVCR: Growth in oncology franchises, global expansion, and profitability targets drive future outlook
Management outlined renewed growth in GBM, strategic launches in pancreatic and lung cancer, and disciplined cost controls. Global expansion is underway, with strong progress in Europe and Japan, and profitability is tar
NEWS | Sep 14, 2026, 08:10 PM UTC
L
NVCR: Strong Optune Pax launch, robust pipeline, and disciplined execution drive growth outlook
Optune Pax's launch for pancreatic cancer exceeded expectations, with strong patient uptake and early payer coverage, while competitive therapies are not expected to significantly impact momentum. Expansion in Japan and
EQUITY | Sep 09, 2026, 03:50 PM UTC
M
NVCR outlook set for double-digit growth on launches, payer gains
Optune Pax’s stage III pancreatic cancer launch exceeded expectations with a 70% prescription-to-active patient conversion and early payer coverage. NVCR also cites Europe and Japan expansion, new clinical trials, and di
EQUITY | Sep 09, 2026, 03:22 PM UTC
L
NovoCure board seat vacated after Scannell retires
NovoCure said director Timothy Scannell retired from its board, with his seat vacated effective Sept. 2, 2026, in an 8-K filing.
REGULATION | Sep 09, 2026, 11:13 AM UTC
L
NVCR - Novocure Announces Upcoming Investor Events
NVCR - Novocure Announces Upcoming Investor Events
EQUITY | Sep 02, 2026, 11:06 AM UTC
L
Novocure to participate in two upcoming investor events
Novocure said management will take part in two upcoming investor events, with live audio webcasts available via its Investor Relations site. Replays will be available for at least 14 days.
EQUITY | Sep 02, 2026, 11:00 AM UTC
L
NVCR data breach affects more than 1,400 cancer patients
NVCR said a data breach affects more than 1,400 cancer patients.
EQUITY | Sep 01, 2026, 02:29 PM UTC
M
Novocure reports unauthorized access to U.S. patient records
Novocure said unauthorized access exposed internal patient ID numbers and other contact data in more than 1,400 U.S. records, with no device access or operational impact.
REGULATION | Sep 01, 2026, 11:03 AM UTC
H
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure Ltd. (NASDAQ: NVCR ) shares rose in Friday’s premarket session before dropping after the company raised its full-year 2026 revenue outlook and reported second-quarter earnings and sales above analyst expectation
EARNINGS | Jul 24, 2026, 03:08 PM UTC
H
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results
U.S. stocks traded lower midway through trading, with the S&P 500 falling over 1% on Thursday. The Dow traded down 0.92% to 51,738.04 while the NASDAQ declined 2.03% to 25,169.19. The S&P 500 also fell, dropping, 1.16% t
CENTRAL_BANK | Jul 23, 2026, 05:31 PM UTC
H
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index dipping around 450 points on Thursday. Shares of Lockheed Martin Corp (NYSE: LMT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 23, 2026, 02:20 PM UTC
H
Transcript: NovoCure Q2 2026 Earnings Conference Call
NovoCure (NASDAQ: NVCR ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire c
EARNINGS | Jul 23, 2026, 01:07 PM UTC
L
NVCR Novocure RESULTS: Q2, Q2 Operating Income $-10.562M, Q2 pretax profit $-12.452M, Q2 REV $183.584M vs. EST $172.4M, Q2 gross profit $142
NVCR Novocure RESULTS: Q2, Q2 Operating Income $-10.562M, Q2 pretax profit $-12.452M, Q2 REV $183.584M vs. EST $172.4M, Q2 gross profit $142.478M, Q2 Net Income $-15.658M
EARNINGS | Jul 23, 2026, 11:14 AM UTC
L
Novocure raises FY26 revenue view to $710M-$725M from $690M-$710M
Raises FY26 adjusted...
EQUITY | Jul 23, 2026, 11:07 AM UTC
L
Novocure reports Q2 EPS (13c), consensus (33c)
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 11:06 AM UTC
H
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NASDAQ: NVCR ) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.
EARNINGS | Jul 23, 2026, 11:01 AM UTC
L
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - GOOGL, CCI, GGG, SON, EPRT, CVBF, CASH, OSBC, OBK
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - GOOGL, CCI, GGG, SON, EPRT, CVBF, CASH, OSBC, OBK, CBAN, BDN, CYH, ACU, LMT, HBAN, LUV, SNA, CLF, LAZ, VC, NVCR, DCOM, AMAL
EARNINGS | Jul 22, 2026, 07:07 PM UTC